Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 25;7(14):3531–3539. doi: 10.1182/bloodadvances.2022009412

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 3. — Detection of ctDNA mutations and evolution during zanubrutinib therapy for 5 patients. Represented is the relative abundance for each detected mutation (plotted as hGE/mL plasma, calculated from AF and plasma cfDNA concentration) and variation over time (x-axis: days). Numbers indicated above the plot at the sample time-points are the calculated total ctDNA (hGE/mL plasma). Associated tables present values for all BTK, PLCG2, TNFAIP3, KMT2D, MYD88, NOTCH2 and TP53 mutations. MZ04 not shown as only one time point (D254) was available for analysis. BD = below detection.